Tier 1 — highest

Effects of Quercetin on Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Dachuan Jin, Shunqin Jin, Tao Zhou, Guoping Sheng, Peng Gao, Guangming Li
Food science & nutrition 2025 13(12):e71358

Bibliography

PubMed
PMID 41404533
PubMed Central
PMC12703814
DOI
10.1002/fsn3.71358
Funding
Reported funding/support: 2024 Zhengzhou Municipal Science and Technology Innovation Guidance Program Project in the Medical and Health Field 2024YLZDJH385 2025 Zhengzhou Municipal Science and Technology Innovation Guidance Program Project in the Medical and Health Field 2025YLZDJH110 FundingThis study received support from the Zhengzhou Science and Technology Bureau through the 2024 Zhengzhou Municipal Science and Technology Innovation Guidance Program Project in the Medical and Health Field (Grant No.: 2024YLZDJH385).
Competing interests
Reported disclosure: The authors declare no conflicts of interest.

Study snapshot

DesignSystematic review and meta-analysis of randomized trials
ModelHuman evidence synthesis
Sample7 trials; 540 patients with MASLD
InterventionQuercetin interventions at trial-specific doses
DurationSearches through January 26, 2025
EndpointsLipid measurements; Inflammatory measures; Liver measurements; Protein activity, binding or signaling

What the study showed, in plain terms

Published in 2025, this source examined liver and metabolic health. Its evidence base was 7 trials; 540 patients with MASLD. It evaluated Quercetin interventions at trial-specific doses across Searches through January 26, 2025.

Selected liver enzymes, lipids, and CRP improved; kidney, body-composition, and several other outcomes did not.

Evidence certainty ranged from very low to moderate. Short surrogate outcomes, small trials, and potentially related reports do not establish fibrosis reversal or fewer liver events.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Weight Loss, Blood Sugar and Fatty Liver: Human Evidence. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Selected liver enzymes, lipids, and CRP improved; kidney, body-composition, and several other outcomes did not.
  • The recorded outcome domains were Lipid measurements; Inflammatory measures; Liver measurements; Protein activity, binding or signaling.
  • This synthesis reuses the included study populations; it is not an additional randomized participant cohort.

What this study can and cannot tell us

  • Evidence certainty ranged from very low to moderate. Short surrogate outcomes, small trials, and potentially related reports do not establish fibrosis reversal or fewer liver events.
  • Pooled estimates depend on the included trials and may share participants with companion publications or other reviews. A statistically significant surrogate outcome does not establish disease prevention.
  • Source basis: Source check: accessible full text and indexed metadata. Missing method details, funding information or participant denominators are not inferred.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology